NO20045037D0 - Fremgangsmate for fremstilling av atorvastatin-kalsium i amorf form - Google Patents
Fremgangsmate for fremstilling av atorvastatin-kalsium i amorf formInfo
- Publication number
- NO20045037D0 NO20045037D0 NO20045037A NO20045037A NO20045037D0 NO 20045037 D0 NO20045037 D0 NO 20045037D0 NO 20045037 A NO20045037 A NO 20045037A NO 20045037 A NO20045037 A NO 20045037A NO 20045037 D0 NO20045037 D0 NO 20045037D0
- Authority
- NO
- Norway
- Prior art keywords
- preparation
- amorphous form
- atorvastatin calcium
- atorvastatin
- calcium
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN491DE2004 | 2004-03-17 |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20045037D0 true NO20045037D0 (no) | 2004-11-19 |
NO20045037L NO20045037L (no) | 2005-09-19 |
NO330092B1 NO330092B1 (no) | 2011-02-14 |
Family
ID=33516010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20045037A NO330092B1 (no) | 2004-03-17 | 2004-11-19 | Fremgangsmate for fremstilling av atorvastatin-kalsium i amorf form |
Country Status (17)
Country | Link |
---|---|
US (1) | US7994343B2 (no) |
EP (3) | EP1577297A1 (no) |
CN (2) | CN1942439B (no) |
AR (1) | AR048271A1 (no) |
AT (1) | ATE545629T1 (no) |
AU (2) | AU2004317570B2 (no) |
CA (3) | CA2666359A1 (no) |
CY (1) | CY1112583T1 (no) |
DK (1) | DK1727795T3 (no) |
ES (1) | ES2381473T3 (no) |
FI (1) | FI120344B (no) |
MY (1) | MY147435A (no) |
NO (1) | NO330092B1 (no) |
PL (1) | PL1727795T3 (no) |
PT (1) | PT1727795E (no) |
SI (1) | SI1727795T1 (no) |
WO (1) | WO2005092852A1 (no) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1577297A1 (en) * | 2004-03-17 | 2005-09-21 | Ranbaxy Laboratories, Ltd. | Process for the production of atorvastatin calcium in amorphous form |
CA2573969C (en) * | 2004-07-16 | 2014-02-04 | Lek Pharmaceuticals D.D. | Oxidative degradation products of atorvastatin calcium |
US7645888B2 (en) * | 2004-08-27 | 2010-01-12 | Biocon Limited | Process for the production of amorphous atorvastatin calcium |
GB2424880A (en) * | 2005-04-06 | 2006-10-11 | Generics | Crystalline forms of atorvastatin sodium, processes for their preparation and their use in inhibiting HMG-CoA reductase |
WO2007020421A1 (en) | 2005-08-15 | 2007-02-22 | Arrow International Limited | Crystalline and amorphous sodium atorvastatin |
GB0613567D0 (en) * | 2006-07-07 | 2006-08-16 | Arrow Int Ltd | Crystalline sodium atorvastatin |
EP1928823B1 (en) | 2005-08-15 | 2014-10-08 | Arrow International Limited | Process for preparing crystalline sodium salt of ATORVASTATIN |
GB0613566D0 (en) * | 2006-07-07 | 2006-08-16 | Arrow Int Ltd | Crystalline sodium atorvastatin |
ES2270722B1 (es) * | 2005-09-15 | 2008-03-01 | Ercros Industrial, S.A. | Procedimiento para la obtencion de atorvastatina calcica amorfa. |
GB0523637D0 (en) * | 2005-11-21 | 2005-12-28 | Avecia Pharmaceuticals Ltd | Process and compounds |
WO2007099552A2 (en) * | 2006-03-02 | 2007-09-07 | Matrix Labaratories Ltd | Novel crystalline form of atovastatin hemi-magnesium |
SI22255A (sl) * | 2006-04-14 | 2007-10-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Novi polimorfi statinovih soli in njihova uporabav farmacevtskih formulacijah |
CN101205209B (zh) * | 2007-12-25 | 2010-06-02 | 浙江新东港药业股份有限公司 | 一种阿伐他汀中间体的精制方法 |
EP2075246A1 (en) * | 2007-12-27 | 2009-07-01 | M. J. Institute of Research | A process for preparation of amorphous form of atorvastatin hemi-calcium salt |
CN101468963B (zh) * | 2007-12-28 | 2012-09-19 | 石药集团中奇制药技术(石家庄)有限公司 | 一种无定形阿伐他汀钙的制备方法 |
KR100850558B1 (ko) * | 2008-01-02 | 2008-08-06 | 조동옥 | 아토르바스타틴의 효율적인 제조방법 |
CN101560177B (zh) * | 2008-04-16 | 2012-10-03 | 北京万全阳光医学技术有限公司 | 一种阿托伐他汀钙的制备方法 |
CN101429195B (zh) * | 2008-11-03 | 2010-12-15 | 华东师范大学 | 一种高纯度阿托伐他汀重要合成中间体的制备方法 |
US8115015B2 (en) | 2009-01-26 | 2012-02-14 | Cadila Healthcare Limited | Process for the preparation of amorphous atorvastatin calcium |
HUE030160T2 (en) * | 2010-04-19 | 2017-05-29 | Dsm Sinochem Pharm Nl Bv | Preparation of atorvastatin with low dietary contamination |
CN102127060B (zh) * | 2010-12-17 | 2013-12-04 | 蚌埠丰原医药科技发展有限公司 | 一种阿托伐他汀钙中间体的制备方法 |
CN102070504A (zh) * | 2010-12-23 | 2011-05-25 | 蚌埠丰原医药科技发展有限公司 | 阿托伐他汀钠的制备方法 |
CN102070505B (zh) * | 2011-01-28 | 2012-01-11 | 海南美大制药有限公司 | 阿托伐他汀钙化合物及其新制法 |
CN103483238B (zh) * | 2013-08-20 | 2014-12-31 | 蚌埠丰原医药科技发展有限公司 | 阿托伐他汀钙三水合物的制备方法 |
CN104945300B (zh) * | 2015-06-17 | 2017-05-10 | 北京嘉林药业股份有限公司 | 一种ⅰ型阿托伐他汀钙的纯化方法 |
WO2017060885A1 (en) * | 2015-10-09 | 2017-04-13 | Laurus Labs Private Limited | An improved process for preparation of atorvastatin or pharmaceutically acceptable salts thereof |
CN106478591B (zh) * | 2016-09-30 | 2018-11-13 | 北京嘉林药业股份有限公司 | 一种阿托伐他汀缩合物中间体的拆分方法 |
CN106432033B (zh) * | 2016-10-21 | 2018-07-27 | 江苏阿尔法药业有限公司 | 一种无定形阿托伐他汀钙的制备方法 |
CN108033899B (zh) * | 2017-12-06 | 2020-04-10 | 浙江科技学院 | 一种(r)-6-氰基-5-羟基-3-羰基己酸叔丁酯的制备方法 |
CN109232355A (zh) * | 2018-10-09 | 2019-01-18 | 河南师范大学 | 一种有效去除阿托伐他汀钙粗品中杂质阿托伐他汀缩合物的方法 |
CN109280024A (zh) * | 2018-10-09 | 2019-01-29 | 河南师范大学 | 一种高纯度阿托伐他汀叔丁酯的制备方法 |
CN110563628B (zh) * | 2019-08-26 | 2022-04-05 | 北京嘉林药业股份有限公司 | 一种双釜制备高纯度和单分散i晶型阿托伐他汀钙的结晶方法 |
CN110776451B (zh) * | 2020-01-02 | 2020-05-22 | 湖南迪诺制药股份有限公司 | 一种i晶型阿托伐他汀钙的制备方法 |
CN113695307B (zh) * | 2020-05-20 | 2022-12-02 | 天津嘉林科医有限公司 | 一种盛放阿托伐他汀钙的玻璃器皿的清洗方法 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5245047A (en) | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5216174A (en) | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5097045A (en) | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5124482A (en) | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
US5003080A (en) | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
US5149837A (en) | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5103024A (en) | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5248793A (en) | 1990-10-17 | 1993-09-28 | Warner-Lambert Company | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5155251A (en) | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
EP0680320B1 (en) * | 1993-01-19 | 1999-04-14 | Warner-Lambert Company | Stable oral ci-981 formulation and process of preparing same |
US5298627A (en) | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
HRP960312B1 (en) * | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
CZ294108B6 (cs) | 1995-07-17 | 2004-10-13 | Warner@Lambertácompany | Krystalická forma I hydrátu atorvastatinuŹ tj@ semivápenaté soli kyseliny [R@}RgŹRgB]@}@fluorfenylB@betaŹdelta@dihydroxy@Q@}�@methylethylB@fenyl[}fenylaminoBkarbonyl]@�H@pyrrol@�@heptanové |
IN191236B (no) | 1999-05-25 | 2003-10-11 | Ranbaxy Lab Ltd | |
HU226640B1 (en) | 1999-10-18 | 2009-05-28 | Egis Gyogyszergyar Nyilvanosan | Process for producing amorphous atorvastatin calcium salt |
US6646133B1 (en) | 2000-10-17 | 2003-11-11 | Egis Gyogyszergyar Rt. | Process for the preparation of amorphous atorvastatin calcium |
SI20425A (sl) | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
WO2001093860A1 (en) | 2000-06-09 | 2001-12-13 | Lek Pharmaceuticals D.D. | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
HUP0303765A2 (hu) | 2000-11-03 | 2004-03-01 | Teva Pharmaceutical Industries Ltd. | Atorvastatin-hemi-kalcium VII forma és eljárás az előállítására |
IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
WO2002057225A2 (en) | 2000-12-18 | 2002-07-25 | Merck & Co., Inc. | Thrombin inhibitors |
CA2626317A1 (en) | 2000-12-27 | 2002-07-04 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of atorvastatin |
WO2002057228A1 (en) | 2001-01-17 | 2002-07-25 | Biocon India Limited | Atorvastatin calcium |
SI20814A (sl) | 2001-01-23 | 2002-08-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Priprava amorfnega atorvastatina |
IN190564B (no) * | 2001-04-11 | 2003-08-09 | Cadila Heathcare Ltd | |
PL367943A1 (en) | 2001-06-29 | 2005-03-07 | Warner-Lambert Company Llc | Crystalline forms of 'r-(r*,r*)!-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
EP2292600A1 (en) | 2001-07-30 | 2011-03-09 | Dr. Reddy's Laboratories Ltd. | Crystaline forms VI and VII of atorvastatin calcium |
US7563911B2 (en) | 2001-08-31 | 2009-07-21 | Morepen Laboratories Ltd. | Process for the preparation of amorphous atorvastin calcium salt (2:1) |
CZ296967B6 (cs) * | 2002-02-01 | 2006-08-16 | Zentiva, A.S. | Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) |
NZ535910A (en) | 2002-03-18 | 2006-04-28 | Biocon Ltd | Preparation of amorphous HMG-CoA reductase inhibitors and hydrates thereof by dissolving a heterogeneous mixture of the enzyme in a hydroxylic solvent and freeze drying |
WO2003099785A1 (en) | 2002-05-28 | 2003-12-04 | Cadila Healthcare Limited | Process for the preparation of amorphous atorvastatin calcium |
SI21302A (sl) | 2002-10-11 | 2004-04-30 | LEK farmacevtska dru�ba d.d. | Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino |
HU227041B1 (en) | 2003-03-24 | 2010-05-28 | Richter Gedeon Nyrt | Process for the synthesis of amorphous atorvastatin calcium |
EP1577297A1 (en) * | 2004-03-17 | 2005-09-21 | Ranbaxy Laboratories, Ltd. | Process for the production of atorvastatin calcium in amorphous form |
TWI321132B (en) | 2004-09-28 | 2010-03-01 | Teva Pharma | Process for preparing forms of atorvastatin calcium substantially free of impurities |
-
2004
- 2004-11-19 EP EP04027584A patent/EP1577297A1/en not_active Withdrawn
- 2004-11-19 SI SI200431843T patent/SI1727795T1/sl unknown
- 2004-11-19 CN CN2004800428343A patent/CN1942439B/zh not_active Expired - Fee Related
- 2004-11-19 EP EP04798913A patent/EP1727795B1/en active Active
- 2004-11-19 CA CA002666359A patent/CA2666359A1/en not_active Abandoned
- 2004-11-19 US US10/549,890 patent/US7994343B2/en not_active Expired - Fee Related
- 2004-11-19 FI FI20041489A patent/FI120344B/fi not_active IP Right Cessation
- 2004-11-19 ES ES04798913T patent/ES2381473T3/es active Active
- 2004-11-19 PT PT04798913T patent/PT1727795E/pt unknown
- 2004-11-19 WO PCT/IB2004/003789 patent/WO2005092852A1/en active Application Filing
- 2004-11-19 DK DK04798913.2T patent/DK1727795T3/da active
- 2004-11-19 NO NO20045037A patent/NO330092B1/no not_active IP Right Cessation
- 2004-11-19 CA CA002560252A patent/CA2560252C/en not_active Expired - Fee Related
- 2004-11-19 AT AT04798913T patent/ATE545629T1/de active
- 2004-11-19 AU AU2004317570A patent/AU2004317570B2/en not_active Ceased
- 2004-11-19 CA CA002627940A patent/CA2627940A1/en not_active Abandoned
- 2004-11-19 PL PL04798913T patent/PL1727795T3/pl unknown
-
2005
- 2005-03-16 AR ARP050101018A patent/AR048271A1/es unknown
- 2005-03-17 CN CNA200580012704XA patent/CN1946688A/zh active Pending
- 2005-03-17 MY MYPI20051161A patent/MY147435A/en unknown
- 2005-09-16 EP EP05077109A patent/EP1659110A1/en not_active Ceased
-
2010
- 2010-12-03 AU AU2010249166A patent/AU2010249166B2/en not_active Ceased
-
2012
- 2012-04-04 CY CY20121100335T patent/CY1112583T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU2010249166A1 (en) | 2010-12-23 |
FI20041489A (fi) | 2006-07-20 |
EP1727795A1 (en) | 2006-12-06 |
MY147435A (en) | 2012-12-14 |
DK1727795T3 (da) | 2012-04-16 |
ES2381473T3 (es) | 2012-05-28 |
CN1946688A (zh) | 2007-04-11 |
AU2004317570B2 (en) | 2011-01-06 |
ATE545629T1 (de) | 2012-03-15 |
EP1577297A1 (en) | 2005-09-21 |
US7994343B2 (en) | 2011-08-09 |
CN1942439B (zh) | 2011-12-21 |
AU2004317570A1 (en) | 2005-10-06 |
CN1942439A (zh) | 2007-04-04 |
CA2627940A1 (en) | 2005-10-06 |
WO2005092852A1 (en) | 2005-10-06 |
SI1727795T1 (sl) | 2012-05-31 |
CA2560252A1 (en) | 2005-10-06 |
CA2560252C (en) | 2009-08-04 |
CA2666359A1 (en) | 2005-10-06 |
NO330092B1 (no) | 2011-02-14 |
AU2010249166B2 (en) | 2012-02-09 |
CY1112583T1 (el) | 2016-02-10 |
PT1727795E (pt) | 2012-04-11 |
FI120344B (fi) | 2009-09-30 |
US20100197941A1 (en) | 2010-08-05 |
EP1659110A1 (en) | 2006-05-24 |
FI20041489A0 (fi) | 2004-11-19 |
EP1727795B1 (en) | 2012-02-15 |
AR048271A1 (es) | 2006-04-12 |
PL1727795T3 (pl) | 2012-06-29 |
NO20045037L (no) | 2005-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20045037L (no) | Fremgangsmate for fremstilling av atorvastatin-kalsium i amorf form | |
NO20070753L (no) | Fremgangsmåte for fremstilling av dihydropteridinoner | |
NO20076030L (no) | Fremgangsmåte for fremstilling av hydroklorsilaner | |
EP1984386A4 (en) | METHODS FOR SYNTHESIZING TWO OR MORE DICARBA BRIDGES IN ORGANIC COMPOUNDS | |
SI1915349T1 (sl) | Postopek za pripravo čistega amorfnega rosuvastatin kalcija | |
IL192241A (en) | A process for making 4 - (benzimidazolylmethylamino) - benzamides and their salts | |
ATE430187T1 (de) | Zusammensetzungen zur wäschebehandlung | |
DE502006004698D1 (de) | Verfahren zur Herstellung von sublithographischen Strukturen | |
DE602005017099D1 (de) | Verfahren zur Herstellung von amorphem Cefuroximaxetil | |
ZA200702965B (en) | Process for forming amorphous atorvastatin | |
EP1793815A4 (en) | AMORPHES ATORVASTATINCALCIUM | |
EP1984385A4 (en) | PROCESS FOR SYNTHESIS OF DICARBABRICES IN ORGANIC COMPOUNDS | |
FI20080427A (fi) | Menetelmä saostetun kalsiumkarbonaatin valmistamiseksi | |
AU2006264650A8 (en) | Zofenopril calcium in polymorph form C | |
PL1753720T3 (pl) | Proces wytwarzania peryndoprylu i jego soli | |
NO20082458L (no) | Fremgangsmåter for fremstilling av cyklopropyl-amidderivat | |
HU0300761D0 (en) | Process for the production of amorphous atorvastatin calcium | |
EP1809313A4 (en) | PROCESS FOR PROMOTING WOUND HEALING | |
ZA200608632B (en) | Process for forming amorphous atorvastatin calcium | |
FR2894958B1 (fr) | Procede de preparation de difluoroethanol | |
IL194876A0 (en) | Crystalline form of atorvastatin calcium stable after storage | |
DE112006001001A5 (de) | Verfahren zur Herstellung von Tetrahydropyran-Derivaten | |
FI20041616A (fi) | Uudet polymeerit ja menetelmä niiden valmistamiseksi | |
EP1804817A4 (en) | METHODS OF PROMOTING WOUND HEALING | |
FR2871166B1 (fr) | Composition thermoplastique biodegradable et procede de preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |